secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001193805-23-001493
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus Q3 revenue $45.1M, net loss narrowed; cash runway extended to 2026; ARCT-154 on track for Japan approval
--------------------------------------------------------------------------------

- Revenue of $45.1M for Q3 2023 ($13.4M in Q3 2022); net loss $16.2M ($0.61/share) improved from $35.3M loss.
- Cash, equivalents and restricted cash $369.1M; expected runway extended to end of 2026.
- $35M milestone achieved from CSL Seqirus; total milestones received $365M to date.
- ARCT-154 monovalent COVID vaccine on track for Japan NDA approval in December; Phase 3 bivalent trial enrollment target (850 participants) reached.
- ARCT-032 Phase 1b initiated; first CF patient dosing this month; FDA Rare Pediatric Disease Designation granted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380523001493/0001193805-23-001493-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380523001493/e619057_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-23-001493

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer